Discontinuation of tyrosine kinase therapy in CML

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Protein tyrosine kinase inhibitors (TKIs) represent a significant advancement in targeted cancer therapy.
• Chronic myeloid leukemia (CML) treatment with TKIs has demonstrated remarkable success, leading to near-normal survival rates for responding patients.

Purpose of the Study:

• To introduce and define the concept of treatment-free remission (TFR) in CML management.
• To establish TFR as a critical endpoint for evaluating future clinical trials in CML.

Main Methods:

• Review of TKI therapy outcomes in chronic myeloid leukemia.
• Analysis of patient response rates and survival data.
• Conceptual development of treatment-free remission as a clinical trial criterion.

Main Results:

• TKIs have transformed CML treatment, achieving high overall survival rates.
• A substantial number of CML patients achieve profound responses, making treatment cessation a viable consideration.
• The concept of treatment-free remission has emerged as a crucial metric for assessing treatment success.

Conclusions:

• Treatment-free remission is a pivotal concept for advancing CML management.
• Achieving TFR in clinical trials is essential for progressing towards a potential cure for CML.
• The focus is shifting towards evaluating the possibility of discontinuing TKI therapy in CML.